Michelle Gilson
Stock Analyst at Morgan Stanley
(1.16)
# 3,455
Out of 4,827 analysts
31
Total ratings
32.14%
Success rate
-6.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Upgrades: Overweight | $10 → $20 | $5.41 | +269.69% | 4 | Jan 9, 2025 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $71.38 | -57.97% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $3.72 | +356.99% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $159.39 | +22.97% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $20.44 | +120.16% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $9.05 | +739.78% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $59.82 | +52.12% | 12 | Mar 1, 2021 |
Vir Biotechnology
Jan 9, 2025
Upgrades: Overweight
Price Target: $10 → $20
Current: $5.41
Upside: +269.69%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $71.38
Upside: -57.97%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $3.72
Upside: +356.99%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $159.39
Upside: +22.97%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $20.44
Upside: +120.16%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $9.05
Upside: +739.78%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $59.82
Upside: +52.12%